New REDUCE-IT data presented at EAS 2026 suggests risk-weighted apoB could better identify residual cardiovascular risk in ...

Cardiosense, a healthcare technology company focused on heart failure care, today announced that the U.S. Food & Drug Administration (FDA) has granted De Novo classification for its PCWP Analysis ...

When researchers pooled data from six major semaglutide weight-loss trials and zeroed in on participants aged 65 and older, ...

Artificial intelligence technologies are advancing the ability to conduct proactive screening to catch the warning signs of serious health conditions, like heart disease. With earlier detection of ...

For World Heart Day 2025, observed annually on Sept. 29 to raise public awareness of cardiovascular diseases and their prevention, Healthcare IT News has been tracking new technologies – and new ...

BOSTON--(BUSINESS WIRE)--Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis software to help physicians diagnose ...

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and ...

WHIPPANY, N.J.--(BUSINESS WIRE)--The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone 1, were ...

In a pragmatic trial, we randomly assigned adults 65 years of age or older who were patients in the Department of Veterans Affairs health system and had been receiving hydrochlorothiazide at a daily ...

In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who ...